Viking Therapeutics Inc (NASDAQ:VKTX) released 52-week histologic data from its Phase 2b VOYAGE study of VK2809 in patients ...

Naz Rahman, an analyst from Maxim Group, maintained the Buy rating on Viking Therapeutics (VKTX – Research Report). The associated price ...

Viking Therapeutics VKTX announced positive 52-week histologic data from the phase IIb VOYAGE study that evaluated VK2809 in patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH). The ...

Viking Therapeutics is pulling up some extra long boats full of reasons the metabolic dysfunction-associated steatohepatitis (MASH) drug VK2809 could be a winner, but executives were mum on exactly ...

The big question surrounding Viking Therapeutics today centers around its promising glucagon-like peptide 1 (GLP-1) drug, ...

(RTTNews) - Viking Therapeutics, Inc. (VKTX) Tuesday reported positive 52-week histologic data from its Phase 2b VOYAGE study of VK2809 in patients with non-alcoholic steatohepatitis (NASH).

Up 260% so far this year, shares of Viking Therapeutics ( VKTX -1.90%) are a hot commodity thanks to its increasingly ...

Several promising drugs in phase 2 testing and beyond seek to offer patients a more convenient alternative to already popular ...

Viking Therapeutics (NASDAQ: VKTX) stock is soaring. Two years ago, the share price hovered just above $2. Today, shares ...

Raymond James raised the price target for the Viking Therapeutics Inc (NASDAQ:VKTX) stock from “an Outperform” to “a Strong buy”. The rating was released on May 16, 2024, according to finviz. We ...

The company may look to license the experimental liver disease drug as it focuses on an obesity treatment that's shown early promise.

The "Undercovered" Dozen highlights ideas from the previous month on stocks with limited coverage. Click here for May 2024’s ...